IRIS Institutional Research Information System - OPENBS Open Archive UniBS

Farina, Mirko
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.979
AS - Asia 3.588
EU - Europa 2.620
SA - Sud America 638
Continente sconosciuto - Info sul continente non disponibili 176
AF - Africa 112
OC - Oceania 18
Totale 13.131
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.656
SG - Singapore 1.448
IT - Italia 1.088
CN - Cina 796
BR - Brasile 512
HK - Hong Kong 336
DE - Germania 321
BD - Bangladesh 302
VN - Vietnam 249
FR - Francia 203
FI - Finlandia 187
GB - Regno Unito 163
CA - Canada 151
RU - Federazione Russa 136
UA - Ucraina 121
TR - Turchia 107
IN - India 95
IE - Irlanda 52
PL - Polonia 52
NL - Olanda 50
MX - Messico 48
SE - Svezia 45
ZA - Sudafrica 44
CZ - Repubblica Ceca 41
JP - Giappone 40
AR - Argentina 38
IQ - Iraq 38
ES - Italia 35
AT - Austria 31
EC - Ecuador 23
CO - Colombia 20
BE - Belgio 19
CR - Costa Rica 19
ID - Indonesia 19
AU - Australia 17
IL - Israele 16
JM - Giamaica 15
SA - Arabia Saudita 15
SV - El Salvador 15
EG - Egitto 14
VE - Venezuela 14
GT - Guatemala 13
TH - Thailandia 12
TT - Trinidad e Tobago 12
UZ - Uzbekistan 12
HN - Honduras 11
LT - Lituania 11
MA - Marocco 11
KR - Corea 9
MY - Malesia 9
PY - Paraguay 9
SC - Seychelles 9
AE - Emirati Arabi Uniti 8
JO - Giordania 8
PE - Perù 8
GR - Grecia 7
KE - Kenya 7
KG - Kirghizistan 7
KZ - Kazakistan 7
NI - Nicaragua 7
NP - Nepal 7
OM - Oman 7
CL - Cile 6
DZ - Algeria 6
EE - Estonia 6
PA - Panama 6
PR - Porto Rico 6
PS - Palestinian Territory 6
PT - Portogallo 6
CH - Svizzera 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
ET - Etiopia 5
HU - Ungheria 5
IR - Iran 5
PH - Filippine 5
RO - Romania 5
SN - Senegal 5
TW - Taiwan 5
UY - Uruguay 5
AL - Albania 4
BS - Bahamas 4
CW - ???statistics.table.value.countryCode.CW??? 4
LB - Libano 4
LK - Sri Lanka 4
LV - Lettonia 4
MD - Moldavia 4
TN - Tunisia 4
AZ - Azerbaigian 3
BB - Barbados 3
BO - Bolivia 3
PK - Pakistan 3
SK - Slovacchia (Repubblica Slovacca) 3
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
GP - Guadalupe 2
HT - Haiti 2
NO - Norvegia 2
AM - Armenia 1
Totale 12.939
Salva come PNG Salva come JPEG
Città #
Singapore 811
Ashburn 713
San Jose 570
Council Bluffs 391
Hong Kong 333
New York 250
Beijing 184
Dallas 181
Fairfield 180
The Dalles 174
Los Angeles 169
Munich 161
Brescia 135
Chandler 118
Helsinki 117
Milan 112
Santa Clara 112
Columbus 97
Lauterbourg 97
Woodbridge 91
Seattle 89
Houston 82
Ho Chi Minh City 80
Jacksonville 80
Wilmington 80
Rome 75
Des Moines 74
Princeton 69
Istanbul 68
São Paulo 63
Hanoi 58
Chicago 56
Buffalo 54
Shanghai 54
Boardman 50
San Francisco 50
Turku 50
Cambridge 47
Dublin 46
North Bergen 46
Phoenix 44
Redondo Beach 44
Toronto 42
Moscow 40
Orem 39
Warsaw 38
Frankfurt am Main 36
London 36
Tokyo 34
Ann Arbor 32
Denver 32
Brooklyn 31
Atlanta 30
Montreal 29
Brno 26
Johannesburg 25
Nuremberg 24
Turin 24
Mexico City 21
Stockholm 20
Boston 19
Romola 19
Chennai 18
Charlotte 17
Paris 17
Poplar 17
Lappeenranta 16
Pune 16
San Diego 16
Manchester 15
San José 15
San Salvador 15
Florence 14
Newark 14
Tianjin 14
Verona 14
Da Nang 13
Nanchang 13
Nanjing 13
Philadelphia 13
Rio de Janeiro 13
Vienna 13
Wroclaw 13
Baghdad 12
Barlassina 12
Bologna 12
Brasília 12
Brussels 12
Mumbai 12
Amsterdam 11
Tashkent 11
Washington 11
Belo Horizonte 10
Biên Hòa 10
Bergamo 9
Dearborn 9
Düsseldorf 9
Genoa 9
Guatemala City 9
Jinan 9
Totale 7.440
Salva come PNG Salva come JPEG
Nome #
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors and Circulating Endothelial Cells in Patients With Primary Myelofibrosis 269
Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia 217
Evaluation of Circulating Endothelial Cells as Direct Marker of Endothelial Damage in Allo-Transplant Recipients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome 208
Comparative Somatic Mutational Profiling of CD34+ Hematopoietic Precursors (HSC) and Circulating Endothelial Cells (CEC) in Patients with Primary Myelofibrosis (PMF) 192
A Gene Panel NGS-Based Strategy for Genomic Characterization of Acute Myeloid Leukemias (AMLs) 191
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial 189
Advances in CMV Management: A Single Center Real-Life Experience 187
Prognostic role of baseline 18F-FDG PET/CT parameters in MALT lymphoma 179
Development of BCR-ABL1 Transgenic Zebrafish Model Reproducing Chronic Myeloid Leukemia (CML) Like-Disease and Providing a New Insight into CML Mechanisms 177
High risk-myelodysplastic syndrome following CAR T-cell therapy in a patient with relapsed diffuse large B cell lymphoma: A case report and literature review 174
Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent 173
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 167
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner? 165
Is the New Tci Score Sufficient to Categorize the Intensity of Conditioning? a Single-Centre Study 163
Liposomal doxorubicin for the treatment of iatrogenic kaposi sarcoma following hematopoietic stem cell transplantation 163
Is Having Clonal Cytogenetic Abnormalities the Same as Having Leukaemia 162
RT-qPCR versus Digital PCR: How Do They Impact Differently on Clinical Management of Chronic Myeloid Leukemia Patients? 160
Bone marrow CD34+ molecular chimerism as an early predictor of relapse after allogeneic stem cell transplantation in patients with acute myeloid leukemia 159
CT-290: Clinical Frailty Scale as a Novel Tool to Evaluate Patients’ Eligibility for Allogeneic Stem Cell Transplant: A Single-Center Experience on 234 Patients >50 Years Old 159
DIGITAL PCR IN PH plus CHRONIC MYELOID LEUKEMIA PATIENTS FOR RECOGNITION OF "STABLE" DEEP MOLECULAR RESPONSE AND IDENTIFICATION OF BEST CANDIDATES TO TKI DISCONTINUATION 158
First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response 156
Multidimensional geriatric assessment for elderly hematological patients (≥60 years) submitted to allogeneic stem cell transplantation. A French-Italian 10-year experience on 228 patients 153
P1450: AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCES HIGHER LEVEL OF EXHAUSTED T-CELLS IN DLBCL PATIENTS BEFORE LEUKAPHERESIS FOR CAR-T CELL THERAPY 149
PB2209: HIGH RISK MYELODYSPLASTIC SYNDROME DEVELOPING IN A PATIENT AFTER CHIMERIC ANTIGEN RECEPTOR (CAR) T- CELL THERAPY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA 148
Case Report: Late Onset of Myelodysplastic Syndrome From Donor Progenitor Cells After Allogeneic Stem Cell Transplantation. Which Lessons Can We Draw From the Reported Case? 146
3-YEARS and Beyond Study Completion Results of the Otpkima Randomized Clinical Trial in Elderly CML Patients 145
Nutritional intervention with TGF-beta enriched food for special medical purposes (TGF-FSMP) is associated with a reduction of malnutrition, acute GVHD, pneumonia and may improve overall survival in patients undergoing allogeneic hematopoietic stem transplantation 144
Autologous Stem Cell Transplantation before Lymphocyte Apheresis for CAR-T Cells Therapy Negatively Impacts on T-Cells Fitness and NK Cell Levels in DLBCL Patients 141
Pre-Emptive Donor Lymphocyte Infusion As Optimal Treatment for Relapsed Acute Myeloid Leukemias and Myelodysplastic Syndromes Following Allogeneic Stem Cell Transplantation: Insights from a French-Italian Study on 134 Patients 141
Identification of Relapse Risk Using a Multiparameter Flow Cytometry-Based Detection of Minimal Residual Disease in Adult Patients with Acute Myeloid Leukemia at ELN Intermediate-Risk 141
IN VIVO STUDY (MYCEC0617) OF CD34+-HSC AND CEC MUTATIONAL PROFILE FOR INVESTIGATING CELL ORIGIN AND PATHOGENESIS OF PRIMARY MYELOFIBROSIS (PMF) 141
ETV6: A Candidate Gene for Predisposition to “Blend Pedigrees”? A Case Report from the NEXT-Famly Clinical Trial 140
Feasibility of Leukemia-Derived Exosome Enrichment and Co-isolated dsDNA Sequencing in Acute Myeloid Leukemia Patients: A Proof of Concept for New Leukemia Biomarkers Detection 138
Impact of transforming growth factor-β2 enriched food for special medical purposes on nutritional status, microbiota and clinical outcomes after allogeneic hematopoietic stem cell transplantation: prospective analysis of 192 consecutive patients 135
Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey) 133
OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY 132
Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol) 131
Comparative monitoring of deep molecular response (DMR) by RT-quantitative (RT-qPCR) and digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) patients treated with TKIs for recognition of stable deep molecular response (DMR) and identification of best candidates to TKIs treatment discontinuation. 129
Immune Reconstitution after Allogenic Stem Cell Transplantation in Patients with Myelofibrosis 127
Timely Leukapheresis May Interfere with the “Fitness” of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients 125
The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors 125
Nutritional strategies to improve VRE control 125
Secondary Myeloid Neoplasms after CD19 CAR-T Cell Therapy: Real-Life Multicenter Data from the Clonhema Study 124
Correlation between BCR::ABL1 Transcript LEVEL in Circulating Extracellular Vesicles and BOTH the Molecular Response and the Ongoing Therapy: A Study on Adult CML Patients 124
Potentiality of Bone Marrow-Derived Mesenchymal Stromal Cells (BM-MSCs) to Differentiate into the Osteogenic Lineage in in Vitro Model of Tissue Regeneration 122
Evaluation of Circulating Endothelial Cells (CECs) As Marker of Endothelial Damage in Allo-Transplanted Patients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS): The Cecinvod Study 121
Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis 120
PF688 JAK2 ALLELIC RATIO IMPACTS ON VASCULAR EVENT IN MYELOFIBROSIS BY INCREASING THE RISK OF THROMBOSIS. A SINGLE CENTER EXPERIENCE ON 150 PATIENTS 117
Malnutrition Prevention after Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT): A Prospective Explorative Interventional Study with an Oral Polymeric Formulation Enriched with Transforming Growth Factor Beta 2 (TGF-β2) 116
BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis 116
Donor Lymphocyte Infusion in the Treatment of Post-Transplant Relapse of Acute Myeloid Leukemias and Myelodysplastic Syndromes Significantly Improves Overall Survival: A French–Italian Experience of 134 Patients 114
Successful CAR-T cell therapy in a refractory MCL patient with bacterial, fungal and COVID-19 infection: a case report 112
PB1959: BCR::ABL1 TRANSCRIPT IN SMALL EXTRACELLULAR VESICLES ISOLATED IN ADULT CHRONIC MYELOID LEUKEMIA PATIENTS CORRELATES WITH MOLECULAR RESPONSE LEVEL AND THE ONGOING THERAPY 112
Outcome of Patients With Acute Myeloid Leukemias or Myelodysplastic Syndromes After Relapsing From Allogeneic Stem Cell Transplantation: The GITMO AML/MDS‐Relapse Registry Study 111
dsDNA from extracellular vesicles (EVs) in adult AML 110
Neuro-toxoplasmosis in haploidentical haematopoietic stem cell transplant 109
CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation 108
How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation 104
Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR) 103
Assessment of Chronic Myeloid Leukaemia In Vitro Models Variability: Insights Into Extracellular Vesicles 101
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan 101
PF404 TUMOR-DERIVED EXOSOMES MAY BE USED AS NEW INFORMATIVE TOOL FOR THE DETECTION OF BONE MARROW RESIDUAL CML LEUKEMIC CELLS ACTIVITY 101
POST REMISSION SEQUENTIAL MONITORING OF MINIMAL RESIDUAL DISEASE BY WT1 Q-PCR AND MULTIPARAMETRIC FLOW CYTOMETRY PREDICTS RELAPSE AND MAY HELP TO ADDRESS THE RISK ADAPTED THERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS 100
In Vitro Biocompatibility Assessment of Bioengineered PLA-Hydrogel Core–Shell Scaffolds with Mesenchymal Stromal Cells for Bone Regeneration 99
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study 97
Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study 97
Real-world outcomes of total body irradiation-based conditioning in allogeneic hematopoietic stem cell transplantation: A single-center retrospective study 96
Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia 96
Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms 94
Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study 93
Exosomes and Extracellular Vesicles in Myeloid Neoplasia: The Multiple and Complex Roles Played by These “Magic Bullets” 92
Assessment of frailty and comorbidities in cellular therapies patients in Italy: results of the GITMO Elderly-Survey (GITMO ELD-Survey) 90
S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY 90
Intensive Chemotherapy Versus Venetoclax-Based Regimens in Elderly Patients with Acute Myeloid Leukemia: Is the Chemotherapy Era Ending? 89
CALRETICULIN MUTATIONS INFLUENCE RESPONSE AND OUTCOME IN TRANSPLANT-AGE MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB 89
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study 88
MALNUTRITION AND GVHD IN ALLOGENIC BONE MARROW TRANSPLANTATION: A PROSPECTIVE STUDY 87
Isolated Cerebral Myeloid Sarcoma in an Allogeneic Stem Cell Transplant Recipient 87
Adult onset hemophagocytic lymphohistiocytosis prognosis is affected by underlying disease and coexisting viral infection: analysis of a single institution series of 35 patients 86
Correction: CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation (Bone Marrow Transplantation, (2023), 10.1038/s41409-023-02124-y) 86
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study 81
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study 80
CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis 79
Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors 77
Successful CAR-T cell therapy in a refractory mcl patient with rapidly progressive disease: a case report 75
Do Unexpected and Cryptic FISH Lesions Of Chromosomally Normal MDS Patients Have Any Prognostic Relevance? 75
A case of Severe Gastrointestinal Toxicity after Allogeneic Hematopoietic Stem Cell Transplantation: Can We Improve the Evaluation of the “Gut Fitness”? 73
Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study 69
INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: PREDICTORS OF RESPONSE AND OUTCOME MAY DRIVE TRANSPLANT DECISION 68
Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50 68
Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study 66
INTERMEDIATE-1 RISK MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: PREDICTORS OF RESPONSE AND OUTCOME MAY DRIVE TRANSPLANT DECISION 66
Digital PCR as a New Method for Minimal Residual Disease Monitoring and Treatment Free Remission Management in Chronic Myeloid Leukemia Patients: Is It Reliable? 66
The possible role of mutated endothelial cells in myeloproliferative neoplasms 66
S157: BCR::ABL1 DIGITAL PCR IDENTIFIES CHRONIC PHASE CML PATIENTS SUITABLE FOR AN EARLY TKI DISCONTINUATION ATTEMPT: A PATIENT-LEVEL META-ANALYSIS 65
Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib 64
Progression-Free Survival but Not Overall Survival Is Superior in Relapsed/Refractory Large B-Cell Lymphomas Treated with Axicabtagene Ciloleucel Compared to Tisagenlecleucel: Results of the CART-SIE Real Life Italian Study 62
Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor? 61
Multicenter real-life evaluation of the Post-CAR prognostic index for patients with large B-cell lymphoma after CAR-T failure 60
Twenty years of evolution of CML therapy: how the treatment goal is moving from disease to patient 58
Totale 11.938
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.704
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.704
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022262 0 0 0 0 13 18 19 39 22 48 22 81
2022/2023445 45 12 17 41 33 88 2 53 55 11 36 52
2023/2024808 31 21 57 52 59 154 43 45 133 27 24 162
2024/20252.506 27 60 57 246 178 181 175 123 400 238 478 343
2025/20266.010 405 549 395 734 587 455 846 308 411 595 356 369
2026/20272.109 333 279 380 970 147 0 0 0 0 0 0 0
Totale 13.131